An experimental Alzheimer's drug outperforms one just approved by the FDA
In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.
Read more on NPR
No comments:
Post a Comment